Sandoz Canada Inc., a Novartis company, continues to innovate with the launch of PrAmiodarone Syringe (PrAmiodarone Hydrochloride for Injection), in a more convenient format for this important medicine which is used in heart rhythm disorders, often used in emergency situations.
PrAmiodarone Syringe in a 3 mL pre-filled syringe (50 mg/mL), is indicated for the initiation of treatment of documented, life-threatening, frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to all other treatment. PrAmiodarone Hydrochloride for Injection should be used for acute treatment until the patient’s ventricular arrhythmias are stabilized.
Sandoz Canada plays a key role in providing medications in life-threatening situations for hospital emergency services, offering nearly 27 products in this area.
"The patient remains central to our decisions. This new pre-filled format meets the needs of health professionals because it will allow faster and safer use of this important medication by reducing handling and the risk of bacterial contamination," said Michel Robidoux, President of Sandoz Canada. "The introduction of this product demonstrates yet again that Sandoz Canada is a committed and trusted partner in the healthcare system. We are making every effort to meet the medical needs of patients while achieving the highest standards of quality, compliance and service, as well as supplying products at minimal cost".
PrAmiodarone Hydrochloride for Injection is also available in vial format manufactured by Sandoz Canada Inc.